Supernus Pharmaceuticals (SUPN) – Analysts’ Recent Ratings Changes

Share on StockTwits

Supernus Pharmaceuticals (NASDAQ: SUPN) has recently received a number of price target changes and ratings updates:

  • 11/12/2018 – Supernus Pharmaceuticals had its price target lowered by analysts at B. Riley from $68.00 to $65.00. They now have a “buy” rating on the stock.
  • 11/8/2018 – Supernus Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
  • 11/7/2018 – Supernus Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 11/7/2018 – Supernus Pharmaceuticals was given a new $57.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/6/2018 – Supernus Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/30/2018 – Supernus Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/22/2018 – Supernus Pharmaceuticals was given a new $56.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/11/2018 – Supernus Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “
  • 10/4/2018 – Supernus Pharmaceuticals was given a new $56.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets SPN-810 and SPN-812 and the bipolar indication opportunity for Oxtellar XR.””

SUPN opened at $42.31 on Tuesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.82 and a quick ratio of 2.65. Supernus Pharmaceuticals Inc has a 52 week low of $34.90 and a 52 week high of $61.25. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of 33.58 and a beta of 0.92.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. Equities analysts expect that Supernus Pharmaceuticals Inc will post 1.87 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. lifted its holdings in Supernus Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 423,062 shares of the specialty pharmaceutical company’s stock valued at $19,376,000 after acquiring an additional 13,238 shares during the period. Bank of Montreal Can lifted its holdings in Supernus Pharmaceuticals by 111.5% in the second quarter. Bank of Montreal Can now owns 79,922 shares of the specialty pharmaceutical company’s stock valued at $4,783,000 after acquiring an additional 42,138 shares during the period. Amalgamated Bank lifted its holdings in Supernus Pharmaceuticals by 14.7% in the second quarter. Amalgamated Bank now owns 8,007 shares of the specialty pharmaceutical company’s stock valued at $479,000 after acquiring an additional 1,028 shares during the period. Hartford Investment Management Co. acquired a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $267,000. Finally, Creative Planning lifted its holdings in Supernus Pharmaceuticals by 27.1% in the second quarter. Creative Planning now owns 20,719 shares of the specialty pharmaceutical company’s stock valued at $1,240,000 after acquiring an additional 4,415 shares during the period. 97.83% of the stock is currently owned by institutional investors.

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: Why do companies engage in swaps?

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.